Choices and Challenges With Treatment of Myasthenia Gravis in Pregnancy: A Systematic Review

Abstract

Myasthenia gravis (MG) is an autoimmune disease affecting young women in their second and third decades, coinciding with their reproductive years. We aim to explore the choices and challenges in the treatment of MG in pregnancy. Cochrane, PubMed, Google Scholar, and Embase were the four databases systematically searched for studies with patients reporting pregnancy outcomes for women with MG during pregnancy using the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) technique. Quality assessment was done using the Joanna Briggs Institute critical tool (JBI, Adelaide, Australia) for methodological quality. From 2000 to 2023, 40 studies from database search results were considered. There is a substantial risk of complications with MG, especially if it appears during pregnancy. In particular, widespread weakness is a cause of severe, life-threatening disorders, but several treatment options are available.

Transient Neonatal Myasthenia Gravis as a Common Complication of a Rare Disease: A Systematic Review

“…In a recent population-based cohort study in the United States, maternal MG was recognized in 1:10,000 deliveries [20]. TNMG affects 15-17% of infants born to mothers with MG based on recent systematic reviews [21,22]. An earlier TNMG rate based on a comprehensive review was 21% [10].…”